Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma
Molecular Cell · 2026-06 · 86 (11) · 2106-2123.e8
DOI: 10.1016/j.molcel.2026.04.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Cell, 2026-06. Verfasst von Kejia Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies…. Hauptthemen laut MEDLINE: Ferroptosis, Phospholipid Hydroperoxide Glutathione Peroxidase, Carcinoma, Hepatocellular, RNA, Long Noncoding. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Targeting ferroptosis, a form of regulated cell death, holds potential for improving treatment efficacy in a range of cancers including hepatocellular carcinoma (HCC). The selenoprotein glutathione peroxidase 4 (GPX4) plays a crucial role in suppressing ferroptosis by converting toxic phospholipid hydroperoxides into non-toxic lipid alcohols, yet the mechanisms regulating its synthesis remain poorly understood. This study identifies SHIELD (suppressor of hypoxia-induced lipid peroxidation and death), a long noncoding RNA (lncRNA) and direct HIF-1α target, as a regulator of ferroptosis in HCC. SHIELD inhibits ferroptosis by interacting with the RNA-binding protein GRSF1, which forms a ternary complex with GPX4 5'-UTR to enhance GPX4 mRNA translation and expression. Furthermore, targeting SHIELD with antisense oligonucleotides (ASOs) in combination with sorafenib significantly reduced tumor growth in patient-derived xenograft models. This discovery paves the way for improving the efficacy of tyrosine kinase inhibitors in HCC, which addresses the challenge of therapeutic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Scien…
- Translational Research Institute, Henan Provincial People's Hospital, Zhengzhou 450053, China.
- Translational Research Institute, Henan Provincial People's Hospital, Zhengzhou 450053, China. Electronic address: wumian@ustc.edu.cn.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Anhui Province
- University of Science and Technology of China
- Chinese Academy of Sciences
- Anhui Provincial Department of Education
Zitieren
APA
Liu, K., Liu, Y., Thorne, R. F., Meng, F., Liu, Y., Wu, M., & Liu, L. (2026). Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma. Molecular Cell, 86(11), 2106-2123.e8. https://doi.org/10.1016/j.molcel.2026.04.026
Vancouver
Liu K, Liu Y, Thorne RF, Meng F, Liu Y, Wu M, et al. Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma. Molecular Cell. 2026;86(11):2106-2123.e8. doi:10.1016/j.molcel.2026.04.026
BibTeX
@article{Liu2026,
author = {Liu, Kejia and Liu, Ying and Thorne, Rick F and Meng, Fanzheng and Liu, Yao and Wu, Mian and Liu, Lianxin},
title = {Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma},
journal = {Molecular Cell},
year = {2026},
volume = {86},
number = {11},
pages = {2106--2123.e8},
doi = {10.1016/j.molcel.2026.04.026}
}
EUVIMED